循环外泌体 SOCS2-AS1 作为一种新型生物标志物在预测冠状动脉疾病诊断中的作用。
Circulating Exosomal SOCS2-AS1 Acts as a Novel Biomarker in Predicting the Diagnosis of Coronary Artery Disease.
机构信息
Department of Cardiovasology, The Affiliated Jiangning Hospital with Nanjing Medical University, 168 Gushan Road, Nanjing, Jiangsu Province, China.
Department of Endocrinology, The Affiliated Jiangning Hospital with Nanjing Medical University, 168 Gushan Road, Nanjing, Jiangsu Province, China.
出版信息
Biomed Res Int. 2020 Apr 9;2020:9182091. doi: 10.1155/2020/9182091. eCollection 2020.
BACKGROUND AND AIMS
Critical roles of circulating exosomal long noncoding RNAs (lncRNAs) have been implicated in multiple diseases. However, little is known about their roles in coronary artery disease (CAD). The aim of the present study was to investigate the relationships between circulating exosomal lncRNAs and CAD and identify the aberrantly expressed disease-related lncRNAs as biomarkers in diagnosing CAD.
METHODS
The aberrantly expressed lncRNAs in plasma exosomes from CAD patients and controls were identified by microarray analysis and verified by quantitative real-time PCR (qRT-PCR). Then, the correlation between the expression level of candidate biomarker and clinic features in CAD patients, mild coronary artery stenosis (mCAS) patients, and controls was analyzed. Finally, we used the receiver operating characteristic (ROC) curve to examine the diagnosis value of candidate biomarkers.
RESULTS
The downregulated SOCS2-AS1 was determined by microarray analysis and verified by qRT-PCR in plasma from CAD patients in contrast to controls. The SOCS2-AS1 expression level in plasma exosomes was negatively correlated with PLT and Lpa. Moreover, CAD patients with elevated levels of plasma exosome-encapsulated SOCS2-AS1 were susceptible to multicoronary artery lesions. Additionally, the area under ROC (AUC) of SOCS2-AS1 was 0.704 (95% CI = 0.607-0.801, < 0.001) for diagnosis of CAD.
CONCLUSIONS
Plasma exosome-encapsulated SOCS2-AS1 was an independent protective factor against CAD and could be potentially used as a novel biomarker for the diagnosis of CAD.
背景与目的
循环外泌体长链非编码 RNA（lncRNA）在多种疾病中发挥着关键作用。然而，其在冠状动脉疾病（CAD）中的作用知之甚少。本研究旨在探讨循环外泌体 lncRNA 与 CAD 的关系，并鉴定出与疾病相关的异常表达 lncRNA 作为诊断 CAD 的生物标志物。
方法
通过微阵列分析鉴定 CAD 患者和对照者血浆外泌体中异常表达的 lncRNA，并通过定量实时 PCR（qRT-PCR）进行验证。然后，分析候选生物标志物表达水平与 CAD 患者、轻度冠状动脉狭窄（mCAS）患者和对照者临床特征之间的相关性。最后，我们使用受试者工作特征（ROC）曲线来评估候选生物标志物的诊断价值。
结果
通过微阵列分析确定 SOCS2-AS1 下调，并通过 qRT-PCR 在 CAD 患者血浆中验证。血浆外泌体中 SOCS2-AS1 的表达水平与 PLT 和 Lpa 呈负相关。此外，血浆外泌体包裹的 SOCS2-AS1 水平升高的 CAD 患者易发生多支冠状动脉病变。此外，SOCS2-AS1 的 ROC 曲线下面积（AUC）为 0.704（95%CI=0.607-0.801， < 0.001），用于诊断 CAD。
结论
血浆外泌体包裹的 SOCS2-AS1 是 CAD 的独立保护因素，可作为诊断 CAD 的新型生物标志物。
Zotero 插件